Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non Operating Income: 2014-2025

Historic Non Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 12 years, with Sep 2025 value amounting to $4.8 million.

  • Catalyst Pharmaceuticals' Non Operating Income fell 24.27% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year increase of 82.37%. This contributed to the annual value of $21.1 million for FY2024, which is 174.57% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Non Operating Income stood at $4.8 million for Q3 2025, which was up 59.20% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Non Operating Income ranged from a high of $11.3 million in Q4 2024 and a low of -$833,000 during Q3 2023.
  • In the last 3 years, Catalyst Pharmaceuticals' Non Operating Income had a median value of $3.0 million in 2025 and averaged $4.0 million.
  • Data for Catalyst Pharmaceuticals' Non Operating Income shows a peak YoY increase of 3,008.45% (in 2022) and a maximum YoY decrease of 622.58% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Non Operating Income stood at $71,000 in 2021, then surged by 3,008.45% to $2.2 million in 2022, then spiked by 127.23% to $5.0 million in 2023, then soared by 126.08% to $11.3 million in 2024, then decreased by 24.27% to $4.8 million in 2025.
  • Its Non Operating Income stands at $4.8 million for Q3 2025, versus $3.0 million for Q2 2025 and $7.9 million for Q1 2025.